抑制CDK2增强CDK4/6抑制剂抗瘤活性在综合性乳腺癌PDX模型屏幕中
Nealia C House1, Maxine M Chen2, Sima Khazaei3
1Blueprint Medicines Corporation, Cambridge, MA, USA. NHouse@blueprintmedicines.com.
NPJ breast cancer
|December 3, 2025
概括
结合CDK2和CDK4/6抑制剂显示出对乳腺癌耐药性的承诺. 这种双重抑制与内分泌治疗一起,在临床前模型和早期临床试验中显示出显著的抗瘤活性.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 异常的环素依赖激酶2 (CDK2) 活性是激素受体阳性 (HR+) /人体表皮生长因子受体2-阴性 (HER2-) 乳腺癌中对CDK4/6抑制剂 (CDK4/6i) 的关键抵抗机制.
- 了解抵抗机制对于提高乳腺癌治疗疗效至关重要.
研究的目的:
- 评估CDK2和CDK4/6联合抑制乳腺癌的临床前和临床活性.
- 为了确定对联合CDK抑制反应的预测生物标志物.
- 评估将内分泌疗法添加到CDK抑制剂组合中的潜力.
主要方法:
- 利用患者衍生的HR+和三阴性乳腺癌的异种移植模型.
- 开发并验证了一种新的mRNA表达特征 (CCND1,CCNE1,RB1,CDKN2A) 来预测反应.
- 使用的组合疗法包括CDK2抑制剂 (CDK2i),CDK4/6抑制剂 (CDK4/6i) 和内分泌疗法.
- 分析了HR+/HER2-乳腺癌患者的早期临床数据,这些患者在组合治疗方案中接受了BLU-222 (一种CDK2i) 治疗.
主要成果:
- CDK2i + CDK4 / 6i组合在CDK4 / 6i耐药和原始HR +和三阴性乳腺癌模型中表现出广泛的抗瘤活性.
- 一个涉及CCND1,CCNE1,RB1和CDKN2A (p16) 的加权mRNA签名有效地预测了对联合CDK抑制的反应.
- 在HR+模型中,添加内分泌疗法显著增强了抗瘤活性.
- 早期临床数据显示,CDK2抑制剂BLU-222在HR+/HER2-乳腺癌患者的单独治疗和与里博西基利布和富尔韦斯特兰特联合治疗中具有活性.
结论:
- 结合CDK2和CDK4/6抑制可以克服乳腺癌中对CDK4/6i的抵抗机制.
- 鉴定到的mRNA签名作为一种潜在的预测生物标志物,用于对联合CDK抑制的反应.
- 包括CDK抑制剂和内分泌治疗在内的联合治疗对治疗HR+/HER2-乳腺癌具有显著的前景.
更多相关视频
06:00Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
Published on: May 14, 2016
11.4K
10:27Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
7.8K
相关概念视频
Inhibition of Cdk Activity
5.5K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K
M-Cdk Drives Transition Into Mitosis
6.2K
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
6.2K
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
Positive Regulator Molecules
6.4K
Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
6.4K
Cancer-Critical Genes II: Tumor Suppressor Genes
9.3K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
9.3K
Mitogens and the Cell Cycle
7.7K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.7K
